Boston Scientific Corporation $BSX Stock: Kintegral Advisory LLC Grows Position

Kintegral Advisory LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 21.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,075 shares of the medical equipment provider’s stock after acquiring an additional 11,298 shares during the period. Kintegral Advisory LLC’s holdings in Boston Scientific were worth $2,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. GraniteShares Advisors LLC lifted its holdings in Boston Scientific by 1.5% in the 1st quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock valued at $853,000 after purchasing an additional 195 shares in the last quarter. Avantax Planning Partners Inc. boosted its stake in Boston Scientific by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock worth $329,000 after purchasing an additional 201 shares during the last quarter. WPG Advisers LLC grew its holdings in shares of Boston Scientific by 11.9% during the first quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock worth $120,000 after buying an additional 203 shares in the last quarter. Natural Investments LLC grew its holdings in shares of Boston Scientific by 1.3% during the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after buying an additional 206 shares in the last quarter. Finally, 180 Wealth Advisors LLC raised its position in shares of Boston Scientific by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after buying an additional 223 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.5%

Shares of BSX stock traded up $0.20 on Friday, hitting $44.34. 12,409,619 shares of the stock traded hands, compared to its average volume of 17,698,992. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a twelve month low of $41.38 and a twelve month high of $105.65. The firm’s 50-day moving average price is $46.06 and its two-hundred day moving average price is $49.76. The stock has a market capitalization of $64.26 billion, a PE ratio of 17.95, a PEG ratio of 1.07 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current year.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. BTIG Research reduced their target price on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating for the company in a research report on Wednesday, September 9th. Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Oppenheimer dropped their price objective on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a research note on Monday, September 21st. Jefferies Financial Group cut their price objective on shares of Boston Scientific from $67.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Mizuho set a $55.00 price objective on shares of Boston Scientific in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $68.23.

Insider Transactions at Boston Scientific

In other news, Director Edward Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 194,522 shares of company stock worth $9,385,210 in the last 90 days. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.